Search filters

List of works by Delphine Rea

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

scientific article

A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.

scientific article

ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery

scientific article published in March 2006

Adenoviral transduction of dendritic cells

scientific article published on 01 January 2005

Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia

scientific article published on 23 February 2012

Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.

scientific article

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

scientific article published on 14 August 2014

BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia

scientific article published on April 2006

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

scientific article published on 26 July 2017

CD34+ progenitors are reproducibly recovered in thawed umbilical grafts and positively influence haematopoietic reconstitution after transplantation

scientific article published on 05 March 2007

Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale

scientific article

Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?

scientific article

Chronic neutrophilic leukemia. A study of four cases

scientific article

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib

scientific article published on 18 August 2015

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

scientific article published in June 2003

Curing chronic myeloid leukemia

scientific article published on June 2012

Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.

scientific article published on 19 May 2016

Dasatinib-induced lupus

scientific article published in August 2008

Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib

scientific article

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity

scientific article

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

scientific article

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

scientific article published on 19 October 2010

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

scientific article

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia

scientific article

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

scientific article

Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells

scientific article

Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation

scientific article published on 21 May 2012

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

scientific article published on 13 January 2015

First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia

scientific article published on 30 March 2012

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

scientific article

Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10

scientific article published on 01 May 2000

Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias

scientific article

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

scientific article published in March 2006

Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells.

scientific article published in April 2001

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy

scientific article

Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia

scientific article

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

scientific article

Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy

scientific article published on 26 February 2009

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

scientific article

Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation

scientific article published on 3 February 2006

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

scientific article

Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: a brief communication

scientific article published in February 2012

Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.

scientific article published in July 2000

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

scientific article

In vivo production of interleukin-10 by malignant cells in AIDS lymphomas

scientific article

Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells

scientific article published on 23 January 2007

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

scientific article

Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission

scientific article published on 09 July 2019

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

scientific article published on 5 May 2016

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

scientific article published on 31 October 2016

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

scientific article published on 06 September 2012

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study

scientific article published on 17 September 2012

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

scientific article published on 04 July 2019

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

scientific article

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

scientific article published on 28 June 2007

Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia

scientific article published on 27 March 2015

Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques

scientific article published on 11 January 2016

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib

scientific article

Microbial contamination of BM products before and after processing: a report of incidence and immediate adverse events in 257 grafts

scientific article published on 01 January 2007

Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.

scientific article published in February 2004

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

scientific article published on 18 May 2017

Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study

scientific article published on 7 January 2015

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

scientific article

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

scientific article

Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.

scientific article

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

scientific article published on 10 June 2013

Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.

scientific article published in August 1994

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

scientific article published on 5 March 2013

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

scientific article

Prolongation of skin graft survival by modulation of the alloimmune response with alternatively activated dendritic cells

scientific article

Prospective flow cytometric evaluation of nucleated red blood cells in cord blood units and relationship with nucleated and CD34(+) cell quantification

scientific article published in March 2006

Quantification of nucleated red blood cells in allogeneic marrow graft and impact of processing on recovery

scientific article published in February 2007

Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.

scientific article

Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10—producing CD4+ T cells

article

Recovery, viability and clinical toxicity of thawed and washed haematopoietic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations

article

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

scientific article published on 24 October 2014

Reply to J. Richter et al.

scientific article published on 28 July 2014

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

scientific article published in October 2013

Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation

scientific article published on 01 May 2007

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

scientific article published on 25 July 2017

Severe peripheral arterial disease during nilotinib therapy.

scientific article

Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia

scientific article published on 28 August 2015

Strategies for improved antigen delivery into dendritic cells

scientific article published on 01 March 2001

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

scientific article published on 3 August 2017

Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia

scientific article published on 8 January 2009

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

scientific article published on 10 December 2010

The self peptide annexin II (208-223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells

scientific article published on 01 February 2001

Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia

scientific article published on 16 September 2013

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience

scientific article

Treatment-free remission in patients with chronic myeloid leukemia

scientific article

Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation

scientific article published on 09 January 2012

Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia

scientific article published on 8 December 2014

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

scientific article published on 18 December 2014

[Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].

scientific article

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

scientific article published on May 1996

Paulina is supported by:

About Paulina

Help